Relevance of Seasonal Revaccination against Respiratory Syncytial Virus in Hematology Patients: First Insights in Stem Cell Transplant Recipients
redjoul, r.; Softic, L.; cabanne, l.; sandillon, g.; robin, c.; ader, m.; ourghanlian, c.; Soocheta, K.; Soulier, A.; Fourati, S.; MAURY, S.
Show abstract
Several vaccines against respiratory syncytial virus (RSV) have been commercialized recently. Their immediate immunogenicity in various conditions of immunosuppression, including patients receiving allogeneic hematopoietic stem cell transplantation (HSCT), have been reported in 2025 by different teams, including ours. In immunocompromised patients, the duration of vaccinal humoral protection as well as the relevance of seasonal revaccination is still unknown. By analyzing the kinetics of humoral responses after a single dose of bivalent RSVpreF vaccine over 12 months in 71 HSCT recipients, we show that annual revaccination benefits mostly those primarily vaccinated within the early 18 months after HSCT. We also provide a first evaluation of vaccinal clinical effectiveness in HSCT patients.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Heterologous vaccination with inactivated and mRNA vaccines increases B and T cell responses to SARS-CoV-2 93%
- Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report 93%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 93%
Similar papers in this journal
- Systems vaccinology identifies clinical and immunological correlates of SARS-CoV-2 vaccine response in solid-organ transplant recipients 94%
- Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19 disease in hamsters 92%
- Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19 92%
Similar papers in this journal
- Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial 93%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 93%
- Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine 93%
Similar papers in this journal
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial 92%
- Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 92%
- Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022 92%
Similar papers in this journal
- Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjects 93%
- Memory B cell and humoral responses elicited by Sputnik V in naïve and COVID-19-recovered vaccine recipients 93%
- Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.